Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB002
- Development stage
- Phase 1
- Lead developer
- Ludwig Cancer Research
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KB002 is a chimeric (engineered) human monoclonal antibody that targets and neutralizes granulocyte macrophage colony-stimulating factor (GM-CSF). By binding to GM-CSF, it inhibits the activity of this cytokine, which plays a key role in inflammation and immune cell activation. The drug was developed as an immunosuppressant for conditions involving excessive or inappropriate immune responses. It was initially developed by Ludwig Institute for Cancer Research and later investigated by KaloBios Pharmaceuticals for diseases such as persistent asthma and chronic immune thrombocytopenic purpura (ITP). Development of KB002 has been discontinued[1][2][3][7].
02
Targets
GM-CSF (Granulocyte-macrophage colony-stimulating factor)
Beyond the preview
Go deeper on KB002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KB002.